Meromax 500/Meromax 1000 Dosage/Direction for Use

The dosage and duration of therapy shall be established depending on type and severity of infection and condition of the patient.
Adults: In the treatment of pneumonia, UTI, gynaecological infections, skin and skin structure infections, the recommended dosage is 500 mg IV every 8 hours.
In the treatment of nosocomial pneumonias, peritonitis, presumed infections in febrile neutropenic patients, septicaemia, the recommended dosage is 1 g every 8 hours.
In the treatment of meningitis, the recommended dosage is 2 g every 8 hours.
Caution is recommended in using meropenem (MEROMAX 500/MEROMAX 1000) as monotherapy in critically ill patients with known or suspected Pseudomonas aeruginosa lower respiratory tract infection.
Use in patients with renal insufficiency: Dosage should be reduced in patients with creatinine clearance less than 51 mL/min as scheduled as follows. (See Table 2.)

Click on icon to see table/diagram/image

Meropenem (MEROMAX 500/MEROMAX 1000) is cleared by haemodialysis; it is recommended that the unit dose (based on the type and severity of infection) is administered at the completion of the haemodialysis procedure.
There is no experience with peritoneal dialysis.
Use in patients with hepatic insufficiency: No dosage adjustment is necessary in patients with impaired hepatic function.
Use in the elderly: No dosage adjustment is required for the elderly with creatinine clearance values above 50 mL/min.
Use in children: For children over 3 months and up to 12 years of age the recommended dose is 10-20 mg/kg IV every 8 hours.
In children over 50 kg weight adult dosage should be used.
In meningitis the recommended dose is 40 mg/kg IV every 8 hours.
Febrile episodes in neutropenic patients-the dose should be 20 mg/kg every 8 hours.
Mode of administration: Intravenous bolus injection: Intravenous bolus injection over approximately 5 minutes.
Meropenem (MEROMAX 500/MEROMAX 1000) to be used for intravenous bolus injection should be constituted with sterile water for injection (5 mL per 250 mg Meropenem (MEROMAX 500/MEROMAX 1000)).
This provides an approximate concentration of 50 mg/mL.
Constituted solution are clear, and colorless or pale yellow.
Intravenous infusion: Intravenous infusion over approximately 15 to 30 minutes. Meropenem (MEROMAX 500/MEROMAX 1000) for intravenous infusion may be constituted with compatible infusion fluids (5 to 200 mL).